Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy

Steffen V.F. Hansen; Elisabeth Christiansen; Christian Urban; Brian D. Hudson; Claire J. Stocker; Maria E. Due-Hansen; Ed T. Wargent; Bharat Shimpukade; Reinaldo Almeida; Christer S. Ejsing; Michael A. Cawthorne; Matthias U. Kassack; Graeme Milligan; Trond Ulven

doi:10.1021/acs.jmedchem.5b01962

Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy

Steffen V.F. Hansen
, Elisabeth Christiansen
, Christian Urban
, Brian D. Hudson
, Claire J. Stocker
, Maria E. Due-Hansen
, Ed T. Wargent
, Bharat Shimpukade
, Reinaldo Almeida
, Christer S. Ejsing
, Michael A. Cawthorne
, Matthias U. Kassack
, Graeme Milligan
, Trond Ulven^*

^*Corresponding author for this work

Aston Medical School

University of Southern Denmark
Heinrich-Heine University
University of Glasgow
University of Buckingham

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes. However, to obtain optimal ligands, it may be necessary to limit both lipophilicity and polar surface area, translating to a need for small compounds. We here describe the identification of 24, a potent FFA1 agonist with low lipophilicity and very high ligand efficiency that exhibit robust glucose lowering effect.

Original language	English
Pages (from-to)	2841-2846
Number of pages	6
Journal	Journal of Medicinal Chemistry
Volume	59
Issue number	6
DOIs	https://doi.org/10.1021/acs.jmedchem.5b01962
Publication status	Published - 24 Mar 2016

Bibliographical note

Publisher Copyright:
© 2016 American Chemical Society.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1021/acs.jmedchem.5b01962

Cite this

Hansen, S. V. F., Christiansen, E., Urban, C., Hudson, B. D., Stocker, C. J., Due-Hansen, M. E., Wargent, E. T., Shimpukade, B., Almeida, R., Ejsing, C. S., Cawthorne, M. A., Kassack, M. U., Milligan, G., & Ulven, T. (2016). Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. Journal of Medicinal Chemistry, 59(6), 2841-2846. https://doi.org/10.1021/acs.jmedchem.5b01962

@article{4b4b1e6ca54a4b9dab7f56b9da490858,

title = "Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy",

abstract = "The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes. However, to obtain optimal ligands, it may be necessary to limit both lipophilicity and polar surface area, translating to a need for small compounds. We here describe the identification of 24, a potent FFA1 agonist with low lipophilicity and very high ligand efficiency that exhibit robust glucose lowering effect.",

author = "Hansen, \{Steffen V.F.\} and Elisabeth Christiansen and Christian Urban and Hudson, \{Brian D.\} and Stocker, \{Claire J.\} and Due-Hansen, \{Maria E.\} and Wargent, \{Ed T.\} and Bharat Shimpukade and Reinaldo Almeida and Ejsing, \{Christer S.\} and Cawthorne, \{Michael A.\} and Kassack, \{Matthias U.\} and Graeme Milligan and Trond Ulven",

note = "Publisher Copyright: {\textcopyright} 2016 American Chemical Society.",

year = "2016",

month = mar,

day = "24",

doi = "10.1021/acs.jmedchem.5b01962",

language = "English",

volume = "59",

pages = "2841--2846",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "6",

}

Hansen, SVF, Christiansen, E, Urban, C, Hudson, BD, Stocker, CJ, Due-Hansen, ME, Wargent, ET, Shimpukade, B, Almeida, R, Ejsing, CS, Cawthorne, MA, Kassack, MU, Milligan, G & Ulven, T 2016, 'Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy', Journal of Medicinal Chemistry, vol. 59, no. 6, pp. 2841-2846. https://doi.org/10.1021/acs.jmedchem.5b01962

TY - JOUR

T1 - Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy

AU - Hansen, Steffen V.F.

AU - Christiansen, Elisabeth

AU - Urban, Christian

AU - Hudson, Brian D.

AU - Stocker, Claire J.

AU - Due-Hansen, Maria E.

AU - Wargent, Ed T.

AU - Shimpukade, Bharat

AU - Almeida, Reinaldo

AU - Ejsing, Christer S.

AU - Cawthorne, Michael A.

AU - Kassack, Matthias U.

AU - Milligan, Graeme

AU - Ulven, Trond

PY - 2016/3/24

Y1 - 2016/3/24

N2 - The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes. However, to obtain optimal ligands, it may be necessary to limit both lipophilicity and polar surface area, translating to a need for small compounds. We here describe the identification of 24, a potent FFA1 agonist with low lipophilicity and very high ligand efficiency that exhibit robust glucose lowering effect.

AB - The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes. However, to obtain optimal ligands, it may be necessary to limit both lipophilicity and polar surface area, translating to a need for small compounds. We here describe the identification of 24, a potent FFA1 agonist with low lipophilicity and very high ligand efficiency that exhibit robust glucose lowering effect.

UR - https://www.scopus.com/pages/publications/84962189595

UR - https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01962

U2 - 10.1021/acs.jmedchem.5b01962

DO - 10.1021/acs.jmedchem.5b01962

M3 - Article

C2 - 26928019

AN - SCOPUS:84962189595

SN - 0022-2623

VL - 59

SP - 2841

EP - 2846

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 6

ER -

Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this